Characterization of a Parkinson’s disease Rat Model Using an Upgraded Paraquat Exposure Paradigm
A Progressive Paraquat-Based Model
Animal models are essential tools for studying how Parkinson’s disease develops and for testing new therapies, yet a persistent challenge has been to obtain a single model that reliably reproduces both the motor and the biochemical features of the human condition. Existing paraquat-based models, in particular, tend to produce only minimal nigrostriatal degeneration at low doses, while high doses cause systemic toxicity that interferes with motor testing. To address this, the authors implemented an upgraded exposure paradigm in which rats received a chronic low dose of paraquat delivered continuously through subcutaneous osmotic minipumps over four weeks, and then characterized the resulting pathology at several time points up to eight weeks.
This approach reproduced the cardinal biochemical and behavioural hallmarks of Parkinson’s disease in a progressive manner. Eight weeks after implantation, the animals showed a significant loss of dopaminergic neurons in the substantia nigra pars compacta, together with a parallel decline in striatal dopamine that deepened over time. This neuronal loss followed a topographical pattern comparable to that seen in human postmortem brains, and it was accompanied by a measurable deficit in motor coordination that could not be explained by reduced overall locomotor activity. Alongside these changes, the model displayed a strong and sustained alpha-synucleinopathy, including increased alpha-synuclein levels, oligomer formation, and phosphorylation at serine 129, as well as early and persistent microglial activation and elevated markers of oxidative stress and oxidative DNA damage.
Overall, these findings show that continuous low-dose paraquat exposure yields a rat model that recapitulates key features of early Parkinson’s disease across dopaminergic, inflammatory, oxidative, and protein-aggregation pathways, while avoiding the systemic toxicity of acute high-dose protocols. Because it reproduces the interplay between these multiple mechanisms over time, the model represents a relevant tool for investigating disease pathogenesis and for validating the efficacy of new therapeutic strategies for Parkinson’s disease.